Market Overview

Biotech Winners And Losers From ASH Conference

Biotech Winners And Losers From ASH Conference

The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements by three biotech companies.


Analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG), with a price target of $159, saying that the ASH was supportive of the company’s “revenue growth targets spread across potential multiple drivers.”

Revlimid would likely remain a growth driver. Goldstein further noted that growth could be generated even without a positive read out for all the potential indications, since its growth potential was spread across multiple opportunities.

“In addition to the existing IMID franchise, data across a number of candidates, including those fully owned (such as CC-486 and CC-220) and those licensed (such as AGI-221, luspatercept, and bb2121), potentially provide multiple levers for growth,” Goldstein wrote.

Bellicum Pharma

Analyst Elemer Piros reiterated a Buy rating on Bellicum Pharmaceuticals Inc (NASDAQ: BLCM), with a price target of $32.

Bellicum Pharma presented updated BPX-501 data in patients receiving haplo-HSCT due to primary immune deficiencies (PIDs) and hemoglobinopathies. “Patients with nonmalignant disease remain alive, achieve effective cures of prior disease, and are GvHD-free,” Piros wrote.

Hemoglobinopathy patients achieved hemoglobin levels that were far superior than that reported by bluebird bio Inc (NASDAQ: BLUE) (Rated: Sell).

“We believe these data with BPX-501 provide strong support for enabling haplo-HSCT for patients as a more viable treatment option in the treatment of non-malignant diseases,” the analyst added.

Seattle Genetics

Analyst Mara Goldstein maintains a Hold rating on Seattle Genetics, Inc. (NASDAQ: SGEN), with a price target of $43, saying that although the company’s ASH presentation was positive, this is already baked into the shares.

Seattle Genetics made multiple presentations on vadastuximab talirine as well as ADCETRIS. The vadastuximab talirine is a positive and could “excite investors;” however, “[we] may be more reserved than others about this dataset given background rate of remission typically observed in the frontline setting for younger patients, and the trial population that included younger patients, with intermediate and adverse cytogenetic risk,” Goldstein mentioned.

The company would be launching a Phase II program in the front-line setting, complementing the existing Phase III in older patients as well as other indications.

At Last Check

Latest Ratings for CELG

Nov 2019DowngradesBuyHold
Nov 2019DowngradesOutperformNeutral
May 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Short Ideas Health Care Reiteration Events Best of Benzinga


Related Articles (BLUE + BLCM)

View Comments and Join the Discussion!

Restoration Hardware Off Lows Of The Session After Q3 Report

Restoration Hardware Still A Fixer-Upper